本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）2024 年员工持股计划（以 下简称"本次员工持股计划"）第一个锁定期于 2025 年 10 月 10 日届满。根据 《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定，现将本次员 工持股计划锁定期届满情况公告如下： 证券代码：300723 证券简称：一品红 公告编号：2025-064 一品红药业集团股份有限公司 关于 2024 年员工持股计划第一个锁定期届满的提示性公告 本次员工持股计划的股票来源为公司回购专用证券账户回购的公司 A 股普 通股股票。本次员工持股计划通过非交易过户的方式过户了 5,116,105 股公司股 票，占公司目前总股本的 1.13%，该部分股票全部来源于上述回购股份。 2、公司季度报告、业绩预告、业绩快报公告前 5 日内； 3、自可能对本公司股票及其衍生品种交易价格产生较大影响的重大事件发 生之日或者进入决策程序之日至依法披露之日； 4、中国证监会及证券交易所 ...

Core Points - The Shanghai Composite Index is at 3927.63 points, slightly down by 0.16%, with a total trading volume of 1.2446 trillion yuan [1] - A total of 181 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Li Min Co., Ltd. (002734) has a deviation rate of 4.31% with a price increase of 6.27% [1] - Yuanda Environmental Protection (600292) shows a deviation rate of 3.35% and a price increase of 3.93% [1] - Oriental Carbon (920175) has a deviation rate of 3.28% with an 8.17% price increase [1] Trading Activity - The total trading volume for A-shares today is reported at 1.2446 trillion yuan [1] - The stocks with the smallest deviation rates include Lian Ke Technology, Lingkang Pharmaceutical, and Publishing Media, which have just crossed the half-year line [1] Deviation Rate Rankings - The top stocks with the highest deviation rates include: - Li Min Co., Ltd. (002734) at 4.31% - Yuanda Environmental Protection (600292) at 3.35% - Oriental Carbon (920175) at 3.28% [1] - Other notable stocks with significant price increases and deviation rates include: - Han Commercial Group (600774) at 3.19% - Rui Pu Biological (300119) at 2.99% [1]

Group 1 - Zhiguang Electric plans to acquire minority stakes in its subsidiary Zhiguang Energy Storage through a combination of share issuance and cash payment, leading to a temporary suspension of its stock trading for up to 10 trading days [1] - Guangbo Co. has been awarded a procurement project by the State Grid Corporation of China, confirming its status as one of the successful bidders for office and industrial supplies [2] - Dongguan Holdings announced the resignation of its chairman Wang Chong'en due to work changes, with Lin Yongsen appointed as the interim chairman [2] Group 2 - *ST Tianmao's stock will be delisted on September 30, 2025, following the Shenzhen Stock Exchange's decision to terminate its listing [3] - Salt Lake Co. has entered the trial production phase for its 40,000 tons/year integrated lithium salt project, successfully producing qualified battery-grade lithium carbonate [5] - Xindazheng plans to adjust its share repurchase price limit from 13.78 yuan to 16.79 yuan per share, maintaining a total repurchase fund of 10 million to 20 million yuan [7] Group 3 - Xindazheng intends to acquire 75.15% of Jiaxin Liheng's equity through share issuance and cash payment, with the transaction price yet to be determined [9] - Koli'er's actual controller plans to reduce his stake by up to 2% of the company's total shares due to funding needs [11] - United Precision's two actual controllers plan to collectively reduce their stake by up to 3% of the company's total shares for personal financial reasons [13] Group 4 - Yipinhong's subsidiary has received a drug registration certificate for L-carnitine oral solution, which is classified as a chemical drug [15] - Tiancheng Self-Control plans to establish a wholly-owned subsidiary in Japan and invest in a warehouse and production base with a budget of up to 10 million yuan [17] - Ningbo Huaxiang's joint venture has obtained a patent license from Jilin University for PEEK technology, which will enhance its R&D capabilities [21] Group 5 - Bright Dairy's subsidiary Synlait Milk Limited plans to sell its North Island assets to Abbott for $170 million, aiming to focus on core business development [23] - Nanjing Pharmaceutical has signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group, with the latter acquiring 11.04% of Nanjing Pharmaceutical's shares [24] - Guoxing Optoelectronics' application for a private placement of A-shares has been accepted by the Shenzhen Stock Exchange [25] Group 6 - Hailianxun has received approval from the China Securities Regulatory Commission for its plan to merge with Hangqilun B through a share exchange [27] - CITIC Bank's risk director Hu Gang has resigned, with Jin Xinian appointed as the new risk director pending regulatory approval [29]

Market Overview - The Shanghai Composite Index is at 3832.05 points, above the six-month moving average, with a slight increase of 0.10% [1] - The total trading volume of A-shares today is 940.447 billion yuan [1] Stocks Performance - A total of 117 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Kaiwang Technology (9.08%) - Liwang Co., Ltd. (6.87%) - Shenghui Technology (6.51%) [1] - Other stocks that have just crossed the six-month moving average with smaller deviation rates include: - China Merchants Securities - Renxin New Materials - Jihigh Development [1] Detailed Stock Data - The top three stocks with the highest daily increase and their respective metrics are: - Kaiwang Technology: 9.71% increase, 7.19% turnover rate, latest price 38.42 yuan [1] - Liwang Co., Ltd.: 13.11% increase, 12.32% turnover rate, latest price 30.03 yuan [1] - Shenghui Technology: 9.64% increase, 9.67% turnover rate, latest price 7.51 yuan [1] - Additional stocks with notable performance include: - Yuejian Intelligent: 5.39% increase, 1.95% turnover rate, latest price 16.03 yuan [1] - Haixing Electric: 4.15% increase, 1.24% turnover rate, latest price 28.13 yuan [1] Additional Stocks with Minor Deviations - Stocks with minor deviations include: - Lingge Technology: 2.11% deviation [2] - Lixin Energy: 1.98% deviation [2] - Fengshan Group: 1.95% deviation [2]

Core Viewpoint - Yipinhong (300723) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, indicating a significant step in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approvals - Yipinhong's subsidiary has obtained a drug registration certificate for L-carnitine oral solution, which is indicated for primary systemic carnitine deficiency and related symptoms [1] - The approved L-carnitine oral solution is classified as a Category B product under the national medical insurance, with an estimated sales scale of approximately 1.257 billion yuan in 2024 [1] - In addition to L-carnitine, Yipinhong has received approvals for several other drugs, including escitalopram oxalate drops (estimated sales of 1.88 billion yuan in 2024) and clindamycin palmitate ester granules (estimated sales of 100 million yuan in 2024) [2][2] - The company has also received approval for oseltamivir phosphate capsules, which are used for the treatment and prevention of influenza in adults and children [2] Group 2: Innovative Drug Development - Yipinhong has disclosed that its innovative drug APH03621, a GnRH receptor antagonist for endometriosis treatment, has received clinical trial registration acceptance [3] - The company is advancing its gout drug AR882, with global Phase III clinical trials expected to complete enrollment by August 2025, and data from these trials anticipated in 2026 [3]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its product, L-Carnitine Oral Solution, which is indicated for the treatment of primary systemic carnitine deficiency [1] Group 1 - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for L-Carnitine Oral Solution [1] - The indication for L-Carnitine Oral Solution is specifically for treating primary systemic carnitine deficiency [1]

Core Viewpoint - The company has received approval for the registration of L-Carnitine oral solution, which is indicated for the treatment of primary systemic carnitine deficiency [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration [1] - The approved product, L-Carnitine oral solution, addresses a specific medical condition, enhancing the company's product portfolio [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, which is indicated for the treatment of primary systemic carnitine deficiency and related conditions [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for L-carnitine oral solution [1] - The approved indication includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children [1] Industry Summary - L-carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The supplement can alleviate metabolic disorders caused by deficiencies, improving the function of skeletal muscle and cardiac tissues [1]

Core Viewpoint - Yipinhong (300723) announced the approval of its oral solution of L-carnitine by the National Medical Products Administration, which is intended for the treatment of primary systemic carnitine deficiency and secondary carnitine deficiency due to congenital metabolic disorders [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., received the drug registration certificate for L-carnitine oral solution [1] - The approved drug is indicated for both short-term and long-term treatment of specific carnitine deficiencies [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of L-Carnitine oral solution, which is indicated for treating primary systemic carnitine deficiency and related conditions [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for L-Carnitine oral solution [1] - The approved indication for L-Carnitine oral solution includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children included in the instructions [1] Group 2: Product Functionality - L-Carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The main functions of L-Carnitine include transporting long-chain fatty acids into the mitochondrial matrix for oxidation and providing energy to cells, as well as exporting short-chain acyl groups produced within the mitochondria [1] - Supplementation of L-Carnitine can alleviate metabolic disorders caused by its deficiency, improving the functionality of skeletal muscle and cardiac tissues [1]